126 related articles for article (PubMed ID: 36842388)
1. The P2X7 purinoceptor in pathogenesis and treatment of dystrophino- and sarcoglycanopathies.
Gόrecki DC; Rumney RMH
Curr Opin Pharmacol; 2023 Apr; 69():102357. PubMed ID: 36842388
[TBL] [Abstract][Full Text] [Related]
2. The Role of P2X7 Purinoceptors in the Pathogenesis and Treatment of Muscular Dystrophies.
Zabłocki K; Górecki DC
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298386
[TBL] [Abstract][Full Text] [Related]
3. P2X7 purinoceptor as a therapeutic target in muscular dystrophies.
Górecki DC
Curr Opin Pharmacol; 2019 Aug; 47():40-45. PubMed ID: 30901735
[TBL] [Abstract][Full Text] [Related]
4. Aberrant Adenosine Triphosphate Release and Impairment of P2Y2-Mediated Signaling in Sarcoglycanopathies.
Benzi A; Baratto S; Astigiano C; Sturla L; Panicucci C; Mamchaoui K; Raffaghello L; Bruzzone S; Gazzerro E; Bruno C
Lab Invest; 2023 Mar; 103(3):100037. PubMed ID: 36925196
[TBL] [Abstract][Full Text] [Related]
5. A novel mechanism of autophagic cell death in dystrophic muscle regulated by P2RX7 receptor large-pore formation and HSP90.
Young CN; Sinadinos A; Lefebvre A; Chan P; Arkle S; Vaudry D; Gorecki DC
Autophagy; 2015; 11(1):113-30. PubMed ID: 25700737
[TBL] [Abstract][Full Text] [Related]
6. Cleavage of β-dystroglycan occurs in sarcoglycan-deficient skeletal muscle without MMP-2 and MMP-9.
Fukai Y; Ohsawa Y; Ohtsubo H; Nishimatsu SI; Hagiwara H; Noda M; Sasaoka T; Murakami T; Sunada Y
Biochem Biophys Res Commun; 2017 Oct; 492(2):199-205. PubMed ID: 28821434
[TBL] [Abstract][Full Text] [Related]
7. eATP/P2X7R Axis: An Orchestrated Pathway Triggering Inflammasome Activation in Muscle Diseases.
Panicucci C; Raffaghello L; Bruzzone S; Baratto S; Principi E; Minetti C; Gazzerro E; Bruno C
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825102
[TBL] [Abstract][Full Text] [Related]
8. Ecto-ATPase activity of alpha-sarcoglycan (adhalin).
Betto R; Senter L; Ceoldo S; Tarricone E; Biral D; Salviati G
J Biol Chem; 1999 Mar; 274(12):7907-12. PubMed ID: 10075685
[TBL] [Abstract][Full Text] [Related]
9. The Danger Signal Extracellular ATP Is Involved in the Immunomediated Damage of α-Sarcoglycan-Deficient Muscular Dystrophy.
Gazzerro E; Baratto S; Assereto S; Baldassari S; Panicucci C; Raffaghello L; Scudieri P; De Battista D; Fiorillo C; Volpi S; Chaabane L; Malnati M; Messina G; Bruzzone S; Traggiai E; Grassi F; Minetti C; Bruno C
Am J Pathol; 2019 Feb; 189(2):354-369. PubMed ID: 30448410
[TBL] [Abstract][Full Text] [Related]
10. Combined Use of CFTR Correctors in LGMD2D Myotubes Improves Sarcoglycan Complex Recovery.
Carotti M; Scano M; Fancello I; Richard I; Risato G; Bensalah M; Soardi M; Sandonà D
Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32155735
[TBL] [Abstract][Full Text] [Related]
11. Different outcome of sarcoglycan missense mutation between human and mouse.
Henriques SF; Patissier C; Bourg N; Fecchio C; Sandona D; Marsolier J; Richard I
PLoS One; 2018; 13(1):e0191274. PubMed ID: 29360879
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular function in alpha-sarcoglycanopathy and gamma-sarcoglycanopathy.
Fayssoil A; Nardi O; Annane D; Orlikowski D
Acta Neurol Belg; 2014 Dec; 114(4):257-9. PubMed ID: 24464767
[TBL] [Abstract][Full Text] [Related]
13. Sarcoglycanopathy: clinical and histochemical characteristics in 66 patients.
Nalini A; Gayathri N; Thaha F; Das S; Shylashree S
Neurol India; 2010; 58(5):691-6. PubMed ID: 21045489
[TBL] [Abstract][Full Text] [Related]
14. P2X7 purinoceptor alterations in dystrophic mdx mouse muscles: relationship to pathology and potential target for treatment.
Young CN; Brutkowski W; Lien CF; Arkle S; Lochmüller H; Zabłocki K; Górecki DC
J Cell Mol Med; 2012 May; 16(5):1026-37. PubMed ID: 21794079
[TBL] [Abstract][Full Text] [Related]
15. Sarcolemmal alpha and gamma sarcoglycan protein deficiencies in Turkish siblings with a novel missense mutation in the alpha sarcoglycan gene.
Diniz G; Tosun Yildirim H; Akinci G; Hazan F; Ozturk A; Yararbas K; Tukun A
Pediatr Neurol; 2014 Jun; 50(6):640-7. PubMed ID: 24742800
[TBL] [Abstract][Full Text] [Related]
16. Sarcoglycanopathies: molecular pathogenesis and therapeutic prospects.
Sandonà D; Betto R
Expert Rev Mol Med; 2009 Sep; 11():e28. PubMed ID: 19781108
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of sarcoglycans, vinculin-talin-integrin system and filamin2 in alpha- and gamma-sarcoglycanopathy: an immunohistochemical study.
Anastasi G; Cutroneo G; Trimarchi F; Santoro G; Bruschetta D; Bramanti P; Pisani A; Favaloro A
Int J Mol Med; 2004 Dec; 14(6):989-99. PubMed ID: 15547664
[TBL] [Abstract][Full Text] [Related]
18. Muscle Diversity, Heterogeneity, and Gradients: Learning from Sarcoglycanopathies.
Sánchez Riera C; Lozanoska-Ochser B; Testa S; Fornetti E; Bouché M; Madaro L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801487
[TBL] [Abstract][Full Text] [Related]
19. CD39 limits P2X7 receptor inflammatory signaling and attenuates sepsis-induced liver injury.
Savio LEB; de Andrade Mello P; Figliuolo VR; de Avelar Almeida TF; Santana PT; Oliveira SDS; Silva CLM; Feldbrügge L; Csizmadia E; Minshall RD; Longhi MS; Wu Y; Robson SC; Coutinho-Silva R
J Hepatol; 2017 Oct; 67(4):716-726. PubMed ID: 28554875
[TBL] [Abstract][Full Text] [Related]
20. β-Sarcoglycan gene transfer decreases fibrosis and restores force in LGMD2E mice.
Pozsgai ER; Griffin DA; Heller KN; Mendell JR; Rodino-Klapac LR
Gene Ther; 2016 Jan; 23(1):57-66. PubMed ID: 26214262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
